Terns Pharmaceuticals Acquired by Merck | Healthcare M&A Deal

Merck has completed the acquisition of Terns Pharmaceuticals, a substance abuse treatment business in Massachusetts, for $53 per share. Merck acquisitions bring Terns’ hematology-focused pipeline and related development capabilities into Merck’s healthcare portfolio, supporting expansion of clinical programs. The Terns Pharmaceuticals acquisition strengthens Merck’s merger acquisition strategy by adding specialized therapeutic assets tied to substance abuse treatment and broader healthcare M&A priorities. This strategic acquisition is a closed merger acquisition with deal size estimated at $50M–$100M, reflecting Merck’s strategic acquisition approach to accelerate pipeline growth.